A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients

Authors
Category Primary study
JournalContemporary Clinical Trials Communications
Year 2021
This article has no abstract
Epistemonikos ID: 5bc5da5c35c7f32a3df93a2980030808c54bf657
First added on: Feb 13, 2025